Respiri

Executive Summary

Respiri is an Australian med-tech company focused on remote patient monitoring (RPM) for chronic respiratory diseases, with its FDA-cleared WheezeRate Detector as the core technology. The device, combined with a HIPAA-compliant SaaS platform, enables healthcare systems to detect exacerbations in asthma and COPD patients early, leveraging CMS-reimbursable CPT codes to generate revenue. With $10M raised and a commercial-stage presence, Respiri addresses the growing demand for cost-effective chronic disease management, aiming to reduce acute care utilization and improve patient outcomes. The company operates in a niche but expanding RPM market, driven by value-based care trends and telehealth adoption. While still private (tickerless), Respiri's focus on a validated sensor and reimbursement pathway positions it for growth, though competition from larger RPM platforms and regulatory risks remain key considerations.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for algorithm update or new indication70% success
• Q4 2026Major health system partnership or pilot expansion50% success
• Q1 2027CMS reimbursement code expansion or policy change40% success